Topic summary
59%33 analyzed articles/videos6,198 analyzed words
BS Summary: These Pharmaceuticals results contain 47 faulty reasoning types, including Negativity Bias, Biased Writer Voice, and Optimism Bias, with Framing Effect as the most egregious example at 13.7% saturation with 4,173 hits. Analysis detected 30,507 faulty-reasoning hits from 30,511 analyzed words across 33 articles, generating a BS Score of 2.1% and a BS Rank of 28% (11,716 of 16,100 topics). This Pharmaceuticals is better (less manipulative) than 72.80% of the peer group.

Ranking context

Position among analyzed topics

27% percentile
025507510027.2% percentile
2.1% BS Score33 analyzed articles30.5K analyzed words

Reasoning profile

Selected profile versus the sitewide rate

TopicSitewideShared scale 0–50%
0.0%10%20%30%40%50%Framing EffectSitewide 26.9%Topic 13.7%13.7%Appeal to EmotionSitewide 15.9%Topic 5.3%5.3%Negativity BiasSitewide 19.2%Topic 9.1%9.1%In-Group BiasSitewide 6.9%Topic 0.2%0.2%Appeal to AuthoritySitewide 11.1%Topic 5.5%5.5%Availability HeuristicSitewide 9.1%Topic 4.1%4.1%Halo EffectSitewide 6.7%Topic 2.0%2.0%Attempt to Sell a Product…Sitewide 0.5%Topic 4.3%4.3%Confirmation BiasSitewide 7.5%Topic 3.9%3.9%AnecdotalSitewide 5.2%Topic 1.9%1.9%

Sitewide departure map

Above the diagonal means this profile uses the pattern more often

0.0%0.0%10%10%20%20%30%30%40%40%50%50%Framing Effect: Topic 13.7%, sitewide 26.9%Negativity Bias: Topic 9.1%, sitewide 19.2%Appeal to Emotion: Topic 5.3%, sitewide 15.9%Appeal to Authority: Topic 5.5%, sitewide 11.1%Availability Heuristic: Topic 4.1%, sitewide 9.1%Hasty Generalization: Topic 5.6%, sitewide 8.1%Confirmation Bias: Topic 3.9%, sitewide 7.5%Biased Writer Voice: Topic 7.0%, sitewide 5.3%In-Group Bias: Topic 0.2%, sitewide 6.9%Halo Effect: Topic 2.0%, sitewide 6.7%Optimism Bias: Topic 6.1%, sitewide 6.0%Anecdotal: Topic 1.9%, sitewide 5.2%Overconfidence Bias: Topic 1.8%, sitewide 4.6%Attempt to Sell a Product or Service: Topic 4.3%, sitewide 0.5%Anchoring Bias: Topic 2.2%, sitewide 4.0%Self-Serving Bias: Topic 1.2%, sitewide 3.7%Ambiguity (Equivocation): Topic 3.5%, sitewide 0.8%Post Hoc (False Cause): Topic 1.9%, sitewide 3.3%Out-Group Homogeneity Bias: Topic 0.1%, sitewide 3.1%Fundamental Attribution Error: Topic 0.5%, sitewide 2.7%Recency Bias: Topic 1.4%, sitewide 2.7%Loss Aversion: Topic 1.0%, sitewide 2.5%Unattributed Quote: Topic 2.4%, sitewide 1.1%Quote-first Misdirection: Topic 2.3%, sitewide 0.0%Framing EffectSitewide rateTopic rate

Analyzed articles and videos

Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill81%
STAT43%By Ed Silverman62%7/24/2026, 10:45:00 AM
In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides77%
STAT43%By Sarah Todd0% Lizzy Lawrence81%7/23/2026, 8:08:56 PM
FDA is urged by advocacy group to ban DTC prescription drug ads59%
STAT43%By Ed Silverman62%7/23/2026, 1:00:00 PM
The next step of site-neutral, and a fiery PBM hearing53%
STAT43%By Bob Herman70%7/20/2026, 2:38:04 PM
Novo Nordisk launches cheaper Ozempic in South Africa78%
Semafor85%By Tiisetso Motsoeneng95%7/20/2026, 12:52:11 PM
Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer69%
STAT43%By Brittany Trang82%7/20/2026, 10:59:00 AM
How this Philly doctor helps patients to save on the cost of medications | Expert Opinion59%
The Philadelphia Inquirer20%By Jules Lipoff79%7/19/2026, 10:01:00 AM
Eli Lilly makes $3.8 billion bet on psychedelic drugs100%
Semafor85%By Tom Chivers86%7/17/2026, 12:54:10 PM
Predicting biotech clinical trials and a new Alzheimer’s drug controversy74%
STAT43%By Elaine Chen14% Adam Feuerstein42% Allison DeAngelis25%7/16/2026, 8:06:43 PM
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley40%
STAT43%By Adam Feuerstein42%7/16/2026, 11:28:27 AM